Article(id=1329868564321906885, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329868547699880929, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2022.11.015, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1660147200000, receivedDateStr=2022-08-11, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794994973496, onlineDateStr=2026-11-18, pubDate=1668009600000, pubDateStr=2022-11-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794994973496, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794994973496, creator=13701087609, updateTime=1794994973496, updator=13701087609, issue=Issue{id=1329868547699880929, tenantId=1146029695717560320, journalId=1319690329412173987, year='2022', volume='43', issue='11', pageStart='1387', pageEnd='1515', issueExtLink='null', onlineDate='null', pubDate='1668009600000', pubDateStr='2022-11-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794994969534, creator='13701087609', updateTime=1794995690665, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329871572984246612, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329868547699880929, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329871572984246613, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329868547699880929, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1475, endPage=1485, ext={EN=ArticleExt(id=1329868564506456262, articleId=1329868564321906885, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Cost-utility analysis of dimethyl fumarate compared with teriflunomide for the treatment of relapsing multiple sclerosis in China, columnId=1325221089055486019, journalTitle=World Clinical Drug, columnName=Article, runingTitle=null, highlight=null, articleAbstract=
Objective

This study aims to evaluate the cost-utility of dimethyl fumarate (DMF) compared with teriflunomide (TFM) for relapsing multiple sclerosis (RMS) in China.

Method

A Markov model was constructed based on a from healthcare system perspective in China over a 37-year horizon. Drug acquisition costs, monitoring costs, disease management costs, disease relapse costs and adverse events management costs were included. QALYs was used as the outcome. Utility of different model statuses and disutility caused by adverse events were also considered in the inputs. Costs and utility inputs were derived from published studies, public documents, and expert interviews. One-way sensitivity analysis (DSA) and probability sensitivity analysis (PSA) were conducted to evaluate the robustness of the results.

Results

Over a 37-year time horizon, DMF led to an incremental QALY gain of 0.16 (4.10 of DMF and vs 3.94 of TFM) and reduced the total cost of ¥128,923 yuan (¥513,105 of DMF and vs ¥642,028 of TFM) compared with TFM. Cost savings are mainly drug acquisition costs, monitoring costs, disease management costs, disease relapse costs and adverse events management costs. DSA results showed that the disability progression hazard ratio values of TFM and DMF were the main drivers. PSA results showed a 100% probability of DMF being cost-effective compared to TFM at a threshold of 1 GDP per capita.

Conclusion

DMF dominates the TFM for the treatment of RMS from healthcare system perspective in China.

, authors=Mingjun RUI1, Xiwen DU1, Li XIE1, Haijun CAO1, Jian YIN2, *, authorsList=Mingjun RUI, Xiwen DU, Li XIE, Haijun CAO, Jian YIN, authorCompany=null, correspAuthors=Jian YIN, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329868564753920199, articleId=1329868564321906885, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=富马酸二甲酯治疗复发缓解型多发性硬化的成本效果分析, columnId=1325221089235841093, journalTitle=世界临床药物, columnName=研究论文, runingTitle=null, highlight=null, articleAbstract=
目的

评估富马酸二甲酯(dimethyl fumarate,DMF)对比特立氟胺(teriflunomide,TFM)治疗复发缓解型多发性硬化的成本效果。

方法

研究从卫生体系角度出发,构建Markov模型模拟患者终生(37年)。成本包括药品成本、监测成本、疾病管理成本、复发治疗成本和不良事件处理成本。结局指标使用质量调整生命年,效用值的选取包括模型状态和不良事件的效用值,参数来自发表文献、公开文件及专家访谈,并对结果进行单因素敏感性分析和概率敏感性分析。

结果

在模拟时限内,DMF组以及TFM组的总成本分别为513 105和642 028元,前者较后者低128 923元,节约主要体现在DMF组有更低的药品、治疗监测、不良事件处理、疾病管理和复发治疗成本。DMF组与TFM组的总质量调整生命年分别为4.10和3.94年,前者较后者增加0.16年。单因素敏感性分析结果显示TFM和DMF的残疾进展风险值是影响结果的主要因素。概率敏感性分析结果显示,在1倍人均GDP的阈值下,DMF相较于TFM具有经济性的概率为100%。

结论

基于卫生体系角度,DMF相较TFM在治疗成人复发缓解型多发性硬化的经济性上具有绝对优势。

, authors=芮明军1, 杜夕雯1, 谢丽1, 曹海俊1, 殷剑2, *, authorsList=芮明军, 杜夕雯, 谢丽, 曹海俊, 殷剑, authorCompany=null, correspAuthors=殷剑, authorNote=

芮明军,硕士,研究方向:药物经济学评价与方法学。

, correspAuthorsNote=
殷剑,主任医师,研究方向:神经免疫学临床研究。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=Tgf0E9a06RH1Pyyo0weozg==, magXml=K1IxXrIxQRIgspcAs3Mkpg==, pdfUrl=null, pdf=CnNmuhR6PeBWA59dknspkA==, pdfFileSize=2082241, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=QTSeLFaAS18chZJkWJf+Gw==, mapNumber=null, fund=null)}, authors=[Author(id=1329868565093658831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329868565164962001, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565093658831, language=EN, stringName=Mingjun RUI, firstName=Mingjun, middleName=null, lastName=RUI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329868565215293650, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565093658831, language=CN, stringName=芮明军, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.天津开心生活科技有限公司,上海 200030, bio={"content":"

芮明军,硕士,研究方向:药物经济学评价与方法学。

"}, bioImg=null, bioContent=

芮明军,硕士,研究方向:药物经济学评价与方法学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329868564951052488, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, xref=1., ext=[AuthorCompanyExt(id=1329868564959441097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China), AuthorCompanyExt(id=1329868564967829706, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.天津开心生活科技有限公司,上海 200030)])]), Author(id=1329868565290791124, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329868565345317078, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565290791124, language=EN, stringName=Xiwen DU, firstName=Xiwen, middleName=null, lastName=DU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329868565416620247, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565290791124, language=CN, stringName=杜夕雯, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.天津开心生活科技有限公司,上海 200030, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329868564951052488, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, xref=1., ext=[AuthorCompanyExt(id=1329868564959441097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China), AuthorCompanyExt(id=1329868564967829706, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.天津开心生活科技有限公司,上海 200030)])]), Author(id=1329868565471146201, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329868565534060763, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565471146201, language=EN, stringName=Li XIE, firstName=Li, middleName=null, lastName=XIE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329868565584392412, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565471146201, language=CN, stringName=谢丽, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.天津开心生活科技有限公司,上海 200030, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329868564951052488, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, xref=1., ext=[AuthorCompanyExt(id=1329868564959441097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China), AuthorCompanyExt(id=1329868564967829706, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.天津开心生活科技有限公司,上海 200030)])]), Author(id=1329868565655695582, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329868565718610144, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565655695582, language=EN, stringName=Haijun CAO, firstName=Haijun, middleName=null, lastName=CAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329868565777330401, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565655695582, language=CN, stringName=曹海俊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.天津开心生活科技有限公司,上海 200030, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329868564951052488, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, xref=1., ext=[AuthorCompanyExt(id=1329868564959441097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China), AuthorCompanyExt(id=1329868564967829706, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.天津开心生活科技有限公司,上海 200030)])]), Author(id=1329868565844439267, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329868565907353829, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565844439267, language=EN, stringName=Jian YIN, firstName=Jian, middleName=null, lastName=YIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329868565974462694, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565844439267, language=CN, stringName=殷剑, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.中国医学科学院老年医学研究院,北京 100730, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329868565018161355, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, xref=2., ext=[AuthorCompanyExt(id=1329868565026549964, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868565018161355, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China), AuthorCompanyExt(id=1329868565034938573, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868565018161355, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医学科学院老年医学研究院,北京 100730)])])], keywords=[Keyword(id=1329868566075125991, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, language=EN, orderNo=1, keyword=dimethyl fumarate), Keyword(id=1329868566133846248, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, language=EN, orderNo=2, keyword=teriflunomide), Keyword(id=1329868566209343721, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, language=EN, orderNo=3, keyword=cost-utility), Keyword(id=1329868566276452586, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, language=EN, orderNo=4, keyword=relapsing multiple sclerosis), Keyword(id=1329868566335172843, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, language=CN, orderNo=1, keyword=富马酸二甲酯), Keyword(id=1329868566393893100, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, language=CN, orderNo=2, keyword=特立氟胺), Keyword(id=1329868566473584877, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, language=CN, orderNo=3, keyword=成本效果), Keyword(id=1329868566557470958, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, language=CN, orderNo=4, keyword=多发性硬化)], refs=[Reference(id=1329868566653939951, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=国家卫生健康委医政医管局. 罕见病诊疗指南: 2019年版[EB/OL]. (2019-09-27) [2022-04-28]. http://www.nhc.gov.cn/yzygj/s7659/201902/61d06b4916c348e0810ce1fceb844333.shtml., articleTitle=null, refAbstract=null), Reference(id=1329868566733631728, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=邱伟, 徐雁. 多发性硬化诊断和治疗中国专家共识(2018版)[J]. 中国神经免疫学和神经病学杂志, 2018, 25(6): 387-394., articleTitle=null, refAbstract=null), Reference(id=1329868566804934897, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Paik J. Diroximel fumarate in relapsing forms of multiple sclerosis: a profile of its use[J]. CNS Drugs, 2021, 35(6): 691-700., articleTitle=null, refAbstract=null), Reference(id=1329868566888820978, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis[J]. Mult Scler Relat Disord, 2016, 9: S5-S48., articleTitle=null, refAbstract=null), Reference(id=1329868566960124147, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Scalfari A, Knappertz V, Cutter G, et al. Mortality in patients with multiple sclerosis[J]. Neurology, 2013, 81(2): 184-192., articleTitle=null, refAbstract=null), Reference(id=1329868567014650100, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=中国罕见病联盟. 中国多发性硬化患者健康洞察蓝皮书暨2021版中国多发性硬化患者生存报告[EB/OL]. [2022-04-28]. http://h5.iooo.net/2021/ms/., articleTitle=null, refAbstract=null), Reference(id=1329868567081758965, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=健康界. 2019年罕见病多发性硬化药物研发及市场现状[EB/OL]. (2019-12-26) [2022-04-28]. https://www.cn-healthcare.com/articlewm/20191225/content-1079814.html., articleTitle=null, refAbstract=null), Reference(id=1329868567157256438, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis[J]. N Engl J Med, 2012, 367(12): 1098-1107., articleTitle=null, refAbstract=null), Reference(id=1329868567220170999, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis[J]. N Engl J Med, 2012, 367(12): 1087-1097., articleTitle=null, refAbstract=null), Reference(id=1329868567308251384, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Tappenden P, Mccabe C, Chilcott J, et al. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the medicare population[J]. Value Health, 2009, 12(5): 657-665., articleTitle=null, refAbstract=null), Reference(id=1329868567383748857, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Mauskopf J, Fay M, Iyer R, et al. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States[J]. J Med Econ, 2016, 19(4): 432-442., articleTitle=null, refAbstract=null), Reference(id=1329868567450857722, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Lunde HMB, Assmus J, Myhr KM, et al. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study[J]. J Neurol Neurosurg Psychiatry, 2017, 88(8): 621-625., articleTitle=null, refAbstract=null), Reference(id=1329868567517966587, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=刘国恩. 中国药物经济学评价指南2020[M]. 北京: 中国市场出版社, 2020: 43-45., articleTitle=null, refAbstract=null), Reference(id=1329868567580881148, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model[J]. BMJ Open, 2014, 4(1): e004073., articleTitle=null, refAbstract=null), Reference(id=1329868567647990013, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Review IFCaE. Final evidence report – Disease-modifying therapies for relapsingremitting and primary-progressive multiple sclerosis: Effectiveness and value[R]. 2017., articleTitle=null, refAbstract=null), Reference(id=1329868567723487486, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Burks J, Marshall TS, Ye X. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis[J]. Clinicoecon Outcomes Res, 2017, 9: 251-260., articleTitle=null, refAbstract=null), Reference(id=1329868567782207743, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Hansen K, Schüssel K, Kieble M, et al. Adherence to disease modifying drugs among patients with multiple sclerosis in Germany: a retrospective cohort study[J]. PLoS One, 2015, 10(7): e0133279., articleTitle=null, refAbstract=null), Reference(id=1329868567853510912, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Xu Y, Mao N, Chirikov V, et al. Cost-effectiveness of teriflunomide compared to interferon beta-1b for relapsing multiple sclerosis patients in China[J]. Clin Drug Investig, 2019, 39(3): 331-340., articleTitle=null, refAbstract=null), Reference(id=1329868567908036865, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=National Institute for Health and Care Excellence. Peginterferon beta-1a for treating relapsing-remitting multiple sclerosis[EB/OL]. [2022-04-28]. https://www.nice.org.uk/guidance/ta624/documents/committee-papers., articleTitle=null, refAbstract=null), Reference(id=1329868567970951426, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Confavreux C, O'connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. The Lancet Neurology, 2014, 13(3): 247-256., articleTitle=null, refAbstract=null), Reference(id=1329868568038060291, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=O'connor P, Li D, Freedman M, et al. A phase Ⅱ study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses[J]. Neurology, 2006, 66(6): 894-900., articleTitle=null, refAbstract=null), Reference(id=1329868568105169156, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Tecfidera (dimethyl fumerate) approved labeling text[EB/OL]. [2022-04-28]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204063s014lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1329868568172278021, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=AUBAGIO (teriflunomide) approved labeling text[EB/OL]. [2022-04-28]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202992s003lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1329868568239386886, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Neurol, 2014, 13(10): 977-986., articleTitle=null, refAbstract=null), Reference(id=1329868568306495751, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=O'connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis[J]. N Engl J Med, 2011, 365(14): 1293-1303., articleTitle=null, refAbstract=null), Reference(id=1329868568415547656, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK[J]. Value Health, 2007, 10(1): 54-60., articleTitle=null, refAbstract=null), Reference(id=1329868568495239433, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Xu R, Insinga RP, Golden W, et al. EuroQol (EQ-5D) health utility scores for patients with migraine[J]. Qual Life Res, 2011, 20(4): 601-608., articleTitle=null, refAbstract=null), Reference(id=1329868568574931210, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=PDB药物综合数据库. 特立氟胺片中标价[EB/OL]. [2022-04-28]. http://pdb.pharmadl.com/Home., articleTitle=null, refAbstract=null), Reference(id=1329868568629457163, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=捷力保4.0报销福利计划[EB/OL]. [2022-04-28]. https://mp.weixin.qq.com/s/byvH_Z54IbjbqnFt0YlM0A., articleTitle=null, refAbstract=null), Reference(id=1329868568688177420, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=上海市卫生健康委员会. 医疗收费标准[EB/OL]. [2022-04-28]. https://www.shanghai.gov.cn/., articleTitle=null, refAbstract=null), Reference(id=1329868568759480589, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=吉建, 张虹, 吕艳艳. 某医院2015—2017年非甾体类抗炎药使用情况分析[J]. 安徽医药, 2020, 24(1): 201-205., articleTitle=null, refAbstract=null), Reference(id=1329868568826589454, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries[J]. Mult Scler J, 2012, 18(S2): 7-15., articleTitle=null, refAbstract=null), Reference(id=1329868568893698319, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=O᾽Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States[J]. BMC Health Serv Res, 2003, 3(1): 1-12., articleTitle=null, refAbstract=null), Reference(id=1329868568948224272, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Chevalier J, Chamoux C, Hammès F, et al. Cost-effectiveness of treatments for relapsing remitting multiple sclerosis: a French societal perspective[J]. PLoS One, 2016, 11(3): e0150703., articleTitle=null, refAbstract=null), Reference(id=1329868569019527441, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=National Institute for Health and Care Excellence. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis[EB/OL]. [2022-04-28]. https://www.nice.org.uk/guidance/TA320., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329868564951052488, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, xref=1., ext=[AuthorCompanyExt(id=1329868564959441097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China), AuthorCompanyExt(id=1329868564967829706, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.天津开心生活科技有限公司,上海 200030)]), AuthorCompany(id=1329868565018161355, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, xref=2., ext=[AuthorCompanyExt(id=1329868565026549964, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868565018161355, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China), AuthorCompanyExt(id=1329868565034938573, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868565018161355, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医学科学院老年医学研究院,北京 100730)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.11.015, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.11.015, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2022.11.015, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2022.11.015, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1668009600000, fullTextJson=null, articleText=null, reference=null)
收藏切换
富马酸二甲酯治疗复发缓解型多发性硬化的成本效果分析
芮明军 1 , 杜夕雯 1 , 谢丽 1 , 曹海俊 1 , 殷剑 2, *
世界临床药物 | 研究论文 2022,43(11): 1475-1485
收起
收藏切换
世界临床药物 |研究论文 2022 , 43 (11) : 1475 -1485
富马酸二甲酯治疗复发缓解型多发性硬化的成本效果分析
全屏
[Author(id=1329868565093658831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329868565164962001, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565093658831, language=EN, stringName=Mingjun RUI, firstName=Mingjun, middleName=null, lastName=RUI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329868565215293650, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565093658831, language=CN, stringName=芮明军, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.天津开心生活科技有限公司,上海 200030, bio={"content":"

芮明军,硕士,研究方向:药物经济学评价与方法学。

"}, bioImg=null, bioContent=

芮明军,硕士,研究方向:药物经济学评价与方法学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329868564951052488, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, xref=1., ext=[AuthorCompanyExt(id=1329868564959441097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China), AuthorCompanyExt(id=1329868564967829706, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.天津开心生活科技有限公司,上海 200030)])]), Author(id=1329868565290791124, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329868565345317078, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565290791124, language=EN, stringName=Xiwen DU, firstName=Xiwen, middleName=null, lastName=DU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329868565416620247, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565290791124, language=CN, stringName=杜夕雯, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.天津开心生活科技有限公司,上海 200030, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329868564951052488, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, xref=1., ext=[AuthorCompanyExt(id=1329868564959441097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China), AuthorCompanyExt(id=1329868564967829706, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.天津开心生活科技有限公司,上海 200030)])]), Author(id=1329868565471146201, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329868565534060763, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565471146201, language=EN, stringName=Li XIE, firstName=Li, middleName=null, lastName=XIE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329868565584392412, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565471146201, language=CN, stringName=谢丽, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.天津开心生活科技有限公司,上海 200030, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329868564951052488, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, xref=1., ext=[AuthorCompanyExt(id=1329868564959441097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China), AuthorCompanyExt(id=1329868564967829706, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.天津开心生活科技有限公司,上海 200030)])]), Author(id=1329868565655695582, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329868565718610144, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565655695582, language=EN, stringName=Haijun CAO, firstName=Haijun, middleName=null, lastName=CAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329868565777330401, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565655695582, language=CN, stringName=曹海俊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.天津开心生活科技有限公司,上海 200030, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329868564951052488, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, xref=1., ext=[AuthorCompanyExt(id=1329868564959441097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China), AuthorCompanyExt(id=1329868564967829706, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868564951052488, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.天津开心生活科技有限公司,上海 200030)])]), Author(id=1329868565844439267, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329868565907353829, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565844439267, language=EN, stringName=Jian YIN, firstName=Jian, middleName=null, lastName=YIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329868565974462694, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, authorId=1329868565844439267, language=CN, stringName=殷剑, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.中国医学科学院老年医学研究院,北京 100730, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329868565018161355, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, xref=2., ext=[AuthorCompanyExt(id=1329868565026549964, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868565018161355, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China), AuthorCompanyExt(id=1329868565034938573, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329868564321906885, companyId=1329868565018161355, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国医学科学院老年医学研究院,北京 100730)])])]
芮明军1, 杜夕雯1, 谢丽1, 曹海俊1, 殷剑2, *
作者信息
  • 1.天津开心生活科技有限公司,上海 200030
  • 2.中国医学科学院老年医学研究院,北京 100730
通讯作者:
殷剑,主任医师,研究方向:神经免疫学临床研究。
作者简介:

芮明军,硕士,研究方向:药物经济学评价与方法学。

Cost-utility analysis of dimethyl fumarate compared with teriflunomide for the treatment of relapsing multiple sclerosis in China
Mingjun RUI1, Xiwen DU1, Li XIE1, Haijun CAO1, Jian YIN2, *
Affiliations
  • 1.Tianjin Happy Life Technology Co., Ltd., Shanghai 200030, China
  • 2.Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
出版时间: 2022-11-10 doi: 10.13683/j.wph.2022.11.015
文章导航
收藏切换
目的

评估富马酸二甲酯(dimethyl fumarate,DMF)对比特立氟胺(teriflunomide,TFM)治疗复发缓解型多发性硬化的成本效果。

方法

研究从卫生体系角度出发,构建Markov模型模拟患者终生(37年)。成本包括药品成本、监测成本、疾病管理成本、复发治疗成本和不良事件处理成本。结局指标使用质量调整生命年,效用值的选取包括模型状态和不良事件的效用值,参数来自发表文献、公开文件及专家访谈,并对结果进行单因素敏感性分析和概率敏感性分析。

结果

在模拟时限内,DMF组以及TFM组的总成本分别为513 105和642 028元,前者较后者低128 923元,节约主要体现在DMF组有更低的药品、治疗监测、不良事件处理、疾病管理和复发治疗成本。DMF组与TFM组的总质量调整生命年分别为4.10和3.94年,前者较后者增加0.16年。单因素敏感性分析结果显示TFM和DMF的残疾进展风险值是影响结果的主要因素。概率敏感性分析结果显示,在1倍人均GDP的阈值下,DMF相较于TFM具有经济性的概率为100%。

结论

基于卫生体系角度,DMF相较TFM在治疗成人复发缓解型多发性硬化的经济性上具有绝对优势。

富马酸二甲酯  /  特立氟胺  /  成本效果  /  多发性硬化
Objective

This study aims to evaluate the cost-utility of dimethyl fumarate (DMF) compared with teriflunomide (TFM) for relapsing multiple sclerosis (RMS) in China.

Method

A Markov model was constructed based on a from healthcare system perspective in China over a 37-year horizon. Drug acquisition costs, monitoring costs, disease management costs, disease relapse costs and adverse events management costs were included. QALYs was used as the outcome. Utility of different model statuses and disutility caused by adverse events were also considered in the inputs. Costs and utility inputs were derived from published studies, public documents, and expert interviews. One-way sensitivity analysis (DSA) and probability sensitivity analysis (PSA) were conducted to evaluate the robustness of the results.

Results

Over a 37-year time horizon, DMF led to an incremental QALY gain of 0.16 (4.10 of DMF and vs 3.94 of TFM) and reduced the total cost of ¥128,923 yuan (¥513,105 of DMF and vs ¥642,028 of TFM) compared with TFM. Cost savings are mainly drug acquisition costs, monitoring costs, disease management costs, disease relapse costs and adverse events management costs. DSA results showed that the disability progression hazard ratio values of TFM and DMF were the main drivers. PSA results showed a 100% probability of DMF being cost-effective compared to TFM at a threshold of 1 GDP per capita.

Conclusion

DMF dominates the TFM for the treatment of RMS from healthcare system perspective in China.

dimethyl fumarate  /  teriflunomide  /  cost-utility  /  relapsing multiple sclerosis
芮明军, 杜夕雯, 谢丽, 曹海俊, 殷剑. 富马酸二甲酯治疗复发缓解型多发性硬化的成本效果分析. 世界临床药物, 2022 , 43 (11) : 1475 -1485 . DOI: 10.13683/j.wph.2022.11.015
Mingjun RUI, Xiwen DU, Li XIE, Haijun CAO, Jian YIN. Cost-utility analysis of dimethyl fumarate compared with teriflunomide for the treatment of relapsing multiple sclerosis in China[J]. World Clinical Drug, 2022 , 43 (11) : 1475 -1485 . DOI: 10.13683/j.wph.2022.11.015

参考文献 引证文献
排序方式:
[1]
国家卫生健康委医政医管局. 罕见病诊疗指南: 2019年版[EB/OL]. (2019-09-27) [2022-04-28]. http://www.nhc.gov.cn/yzygj/s7659/201902/61d06b4916c348e0810ce1fceb844333.shtml.
[2]
邱伟, 徐雁. 多发性硬化诊断和治疗中国专家共识(2018版)[J]. 中国神经免疫学和神经病学杂志, 2018, 25(6): 387-394.
[3]
Paik J. Diroximel fumarate in relapsing forms of multiple sclerosis: a profile of its use[J]. CNS Drugs, 2021, 35(6): 691-700.
[4]
Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis[J]. Mult Scler Relat Disord, 2016, 9: S5-S48.
[5]
Scalfari A, Knappertz V, Cutter G, et al. Mortality in patients with multiple sclerosis[J]. Neurology, 2013, 81(2): 184-192.
[6]
中国罕见病联盟. 中国多发性硬化患者健康洞察蓝皮书暨2021版中国多发性硬化患者生存报告[EB/OL]. [2022-04-28]. http://h5.iooo.net/2021/ms/.
[7]
健康界. 2019年罕见病多发性硬化药物研发及市场现状[EB/OL]. (2019-12-26) [2022-04-28]. https://www.cn-healthcare.com/articlewm/20191225/content-1079814.html.
[8]
Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis[J]. N Engl J Med, 2012, 367(12): 1098-1107.
[9]
Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis[J]. N Engl J Med, 2012, 367(12): 1087-1097.
[10]
Tappenden P, Mccabe C, Chilcott J, et al. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the medicare population[J]. Value Health, 2009, 12(5): 657-665.
[11]
Mauskopf J, Fay M, Iyer R, et al. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States[J]. J Med Econ, 2016, 19(4): 432-442.
[12]
Lunde HMB, Assmus J, Myhr KM, et al. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study[J]. J Neurol Neurosurg Psychiatry, 2017, 88(8): 621-625.
[13]
刘国恩. 中国药物经济学评价指南2020[M]. 北京: 中国市场出版社, 2020: 43-45.
[14]
Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model[J]. BMJ Open, 2014, 4(1): e004073.
[15]
Review IFCaE. Final evidence report – Disease-modifying therapies for relapsingremitting and primary-progressive multiple sclerosis: Effectiveness and value[R]. 2017.
[16]
Burks J, Marshall TS, Ye X. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis[J]. Clinicoecon Outcomes Res, 2017, 9: 251-260.
[17]
Hansen K, Schüssel K, Kieble M, et al. Adherence to disease modifying drugs among patients with multiple sclerosis in Germany: a retrospective cohort study[J]. PLoS One, 2015, 10(7): e0133279.
[18]
Xu Y, Mao N, Chirikov V, et al. Cost-effectiveness of teriflunomide compared to interferon beta-1b for relapsing multiple sclerosis patients in China[J]. Clin Drug Investig, 2019, 39(3): 331-340.
[19]
National Institute for Health and Care Excellence. Peginterferon beta-1a for treating relapsing-remitting multiple sclerosis[EB/OL]. [2022-04-28]. https://www.nice.org.uk/guidance/ta624/documents/committee-papers.
[20]
Confavreux C, O'connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. The Lancet Neurology, 2014, 13(3): 247-256.
[21]
O'connor P, Li D, Freedman M, et al. A phase Ⅱ study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses[J]. Neurology, 2006, 66(6): 894-900.
[22]
Tecfidera (dimethyl fumerate) approved labeling text[EB/OL]. [2022-04-28]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204063s014lbl.pdf.
[23]
AUBAGIO (teriflunomide) approved labeling text[EB/OL]. [2022-04-28]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202992s003lbl.pdf.
[24]
Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Neurol, 2014, 13(10): 977-986.
[25]
O'connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis[J]. N Engl J Med, 2011, 365(14): 1293-1303.
[26]
Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK[J]. Value Health, 2007, 10(1): 54-60.
[27]
Xu R, Insinga RP, Golden W, et al. EuroQol (EQ-5D) health utility scores for patients with migraine[J]. Qual Life Res, 2011, 20(4): 601-608.
[28]
PDB药物综合数据库. 特立氟胺片中标价[EB/OL]. [2022-04-28]. http://pdb.pharmadl.com/Home.
[29]
捷力保4.0报销福利计划[EB/OL]. [2022-04-28]. https://mp.weixin.qq.com/s/byvH_Z54IbjbqnFt0YlM0A.
[30]
上海市卫生健康委员会. 医疗收费标准[EB/OL]. [2022-04-28]. https://www.shanghai.gov.cn/.
[31]
吉建, 张虹, 吕艳艳. 某医院2015—2017年非甾体类抗炎药使用情况分析[J]. 安徽医药, 2020, 24(1): 201-205.
[32]
Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries[J]. Mult Scler J, 2012, 18(S2): 7-15.
[33]
O᾽Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States[J]. BMC Health Serv Res, 2003, 3(1): 1-12.
[34]
Chevalier J, Chamoux C, Hammès F, et al. Cost-effectiveness of treatments for relapsing remitting multiple sclerosis: a French societal perspective[J]. PLoS One, 2016, 11(3): e0150703.
[35]
National Institute for Health and Care Excellence. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis[EB/OL]. [2022-04-28]. https://www.nice.org.uk/guidance/TA320.
2022年第43卷第11期
12
2
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2022.11.015
  • 接收时间:2022-08-11
  • 首发时间:2026-11-18
  • 出版时间:2022-11-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-08-11
基金
作者信息
    1.天津开心生活科技有限公司,上海 200030
    2.中国医学科学院老年医学研究院,北京 100730

通讯作者:

殷剑,主任医师,研究方向:神经免疫学临床研究。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2022.11.015
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏